RE:RE:RE:The 10% Edison ConjectureWell now, there ya go, md.
There are lots of valuations that could be worked out, and competently defended.
If xB3-001 works then it could bring in billions per year. Implicit in that is that because xB3 can transport any number of additional drugs across the BBB, then Bioasis is almost impossible to valuate.
However difficult it is to valuate now, I'm very interested to see how the market goes about it if we have successful phase 1b and phase 2 trials.
I posted about financing models and possibilities 2 weeks ago or so. Multiple scenarios. All there. Maybe we could discuss it all.
jdstox